Drugs / CoV2 preS dTM/D614
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05289037 | Mar 2022 → Nov 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoV2 preS dTM/D614 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05289037 ↗ |
| Modality | Protein / enzyme biologic | “liquid formulation made of recombinant protein” NCT05289037 ↗ |
| Route | Intramuscular | “administered through intramuscular injection” NCT05289037 ↗ |